Genprex

News

The Power Behind Gene Therapy Drug Combinations

Genprex is harnessing the power of a combinational treatment approach to overcome treatment limitations and offer patients new treatment options.

Read More

Austin’s Genprex raises $25.5M with 2 stock offerings

Austin-based biotech firm Genprex is looking for more growth after raising about $25.5 million through two recent stock offerings.

Read More

Genprex, Inc. Announces Closing of $17,500,000 Common Stock Offering At-The-Market and Without Warrants

The Company intends to use the net proceeds from the offering to advance its drug development programs and for working capital and general corporate purposes.

Read More

Genprex, Inc. Prices $17,500,000 Common Stock Offering Priced At-The-Market and Without Warrants

The closing of the registered direct offering is expected to take place on or about February 21, 2020, subject to the satisfaction of customary closing conditions.

Read More

Drug Candidate for Lung Cancer Receives FDA Fast Track Designation

Technology Networks spoke with Rodney Varner, CEO of Genprex, to learn more about the next steps for Oncoprex and how the FDA Fast Track Designation will facilitate the delivery of this drug to cancer patients.

Read More

UPMC Children’s Hospital Researchers Working On ‘Groundbreaking’ Procedure To Cure Diabetes

Thirty million Americans are living with diabetes and hoping someday to be cured. That day could come sooner than expected, thanks to a team of researchers at UPMC Children’s Hospital of Pittsburgh.

Read More

Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes

Genprex signed an exclusive license agreement with the University of Pittsburgh for a diabetes gene therapy that may have the potential to cure Type 1 and Type 2 diabetes, which together currently affect approximately 30.3 million people in the U.S, or 9 percent of the U.S. population.

Read More

Genprex to Focus on Developing Immunogene Therapy, Start Lung Cancer Trials This Year

Genprex said that after receiving the US Food and Drug Administration’s fast track designation last month for its immunogene therapy Oncoprex in combination with the EGFR tyrosine kinase inhibitor (TKI) osimertinib (AstraZeneca’s Tagrisso), the clinical-stage gene therapy company is prioritizing development of this therapy combination for EGFR-mutated non-small cell lung cancer.

Read More

Genprex Regains Compliance with Nasdaq Minimum Bid Price Requirement

Genprex announced that it received notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule.

Read More

Genprex to Focus Its Clinical Efforts on Oncoprex™ in Combination Therapy with Osimertinib for Non-Small Cell Lung Cancer (NSCLC)

Genprex provides a clinical update and focus for its Oncoprex™ immunogene therapy program for 2020, prioritizing the development of Oncoprex in combination with osimertinib for the treatment of non-small cell lung cancer (NSCLC).

Read More